Turning Point sinks on ASCO update for repotrectinib

Updated data showing a lower response rate in a cohort of ROS1-positive NSCLC patients treated with repotrectinib than a previous analysis and a death possibly related to treatment sent shares of Turning Point tumbling on the first day of the American Society of Clinical Oncology meeting in Chicago.